IgG-assisted age-dependent clearance of Alzheimer's amyloid β peptide by the blood-brain barrier neonatal Fc receptor

Journal of Neuroscience

Volumn 25, Issue 50, 2005, Pages 11495-11503

  Deane, Rashid ^a   Sagare, Abhay ^a   Hamm, Katie ^a   Parisi, Margaret ^a   LaRue, Barbra ^a   Guo, Huang ^a   Wu, Zhenhua ^a   Holtzman, David M ^b   Zlokovic, Berislav V ^a,c  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Box 670 ^*  (United States)

Author keywords

Alzheimer's disease; Amyloid; Amyloid ; Antibody; Blood brain barrier; Transport

Indexed keywords

AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-40]; FC RECEPTOR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG CLEARANCE; GENE DELETION; GROUPS BY AGE; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; TRANSCYTOSIS; WILD TYPE;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ANIMALS, NEWBORN; BLOOD-BRAIN BARRIER; BRAIN; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOGLOBULIN G; IMMUNOTHERAPY; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; RECEPTORS, FC;

EID: 30844472909     PISSN: 02706474     EISSN: 02706474     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.3697-05.2005     Document Type: Article

References (56)

1. Bacskai BJ, Kajdasz ST, Christie RH, Carter C, Games D, Seubert P, Schenk D, Hyman BT (2001) Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med 7:369-372.
2. Bacskai BJ, Kajdasz ST, McLellan ME, Games D, Seubert P, Schenk D, Hyman BT (2002) Non-Fc-mediated mechanisms are involved in the clearance of amyloid-β in vivo by immunotherapy. J Neurosci 22:7873-7878.
3. Balin BJ, Broadwell RD, Salcman M, El-Kalliny M (1986) Avenues for entry of peripherally administered protein to the central nervous system in mouse, rat and squirrel monkey. J Comp Neurol 251:260-280.
4. Banks WA, Terrell B, Farr SA, Robinson SM, Nonaka N, Morley JE (2002) Passage of amyloid β protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease. Peptides 23:2223-2226.
5. Banks WA, Robinson SM, Verma S, Morley JE (2003) Efflux of human and mouse amyloid β proteins 1-40 and 1-42 from brain: impairment in a mouse model of Alzheimer's disease. Neuroscience 121:487-492.
6. Banks WA, Pagliari P, Nakaoke R, Morley JE (2005) Effects of behaviorally active antibody on the brain uptake and clearance of amyloid beta proteins. Peptides 26:287-294.
7. Bard F, Cannon C, Barbour R, Burke R, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, et al. (2000) Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer's disease. Nat Med 6:916-919.
8. 1-[(7S)-5- methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide]. J Pharmacol Exp Ther 313:902-908.
9. Borvak J, Richardson J, Medesan C, Antoke F, Radu C, Simionescu M, Ghetie V, Ward S (1998) Functional expression of the MHC class 1-related receptor, FcRn, in endothelial cells of mice. Int Immunology 10:1289-1298.
10. Broadwell RD, Sofroniew MV (1993) Serum proteins bypass the blood-brain fluid barriers to extracellular entry to the central nervous system. Exp Neurol 120:245-263.
11. Cirrito JR, May PC, O'Dell MA, Taylor JW, Parsadanian M, Cramer JW, Audia JE, Nissen JS, Bales KR, Paul SM, DeMattos RB, Holtzman DM (2003) In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-β metabolism and half-life. J Neurosci 23:8844-8853.
12. Das P, Murphy MP, Younkin LH, Younkin SG, Golde TE (2001) Reduced effectiveness of Aβ 1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol Aging 22:721-727.
13. -/- knock-out mice. J Neurosci 23:8532-8538.
14. Deane R, Yan SD, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, et al. (2003) RAGE mediates amyloid-β transport across the blood-brain barrier and accumulation in brain. Nat Med 9:907-913.
15. Deane R, Wu Z, Sagare A, Davis J, Yan SD, Hamm K, Xu F, Parisi M, LaRue B, Hu HW, Spijkers P, Guo H, Song X, Lenting PJ, Van Nostrand WE, Zlokovic BV (2004) LRP/amyloid β-peptide interaction mediates differential brain efflux of Aβ isoforms. Neuron 43:333-344.
16. DeMattos RB, Bales KR, Cummins DJ, Dodart J, Paul SM, Holtzman DM (2001) Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 98:8850-8855.
17. DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM (2002) Brain to plasma amyloid-Aβ efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 295:2264-2267.
18. Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM (2002) Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model. Nat Neurosci 5:452-457.
19. Frautschy SA, Cole GM, Baird A (1992) Phagocytosis and deposition of vascular β-amyloid in rat brains injected with Alzheimer β-amyloid. Am J Pathol 140:1389-1399.
20. Gafencu A, Heltianu C, Burlacu A, Hunziker W, Simionescu M (2003) Investigation of IgG receptors expression on the surface of human placental endothelial cells. Placenta 24:664-676.
21. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353-356.
22. Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Muller-Tillmanns B, Lemka U, Henke K, Moritz E, Garcia E, Wollmer MA, Umbricht D, deq Uervain JF, Hofmann M, Maddalena A, Papassotiropoulos A, Nitsch RM (2003) Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38:547-554.
23. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G (1996) Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274:99-102.
24. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HTJ, Nixon RA, Mercken M, Bergeron C, Fraser PE, St. George- Hyslop P, Westaway D (2000) Aβ peptide immunization reduces behavioral impairment and plaques in a model of Alzheimer's disease. Nature 408:979-982.
25. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG (2001) Age-dependent changes in brain, CSF, and plasma amyloid Aβ protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 21:372-381.
26. Kayed R, Head E, Thompson JL, Mclntire TM, Milton SC, Cotman CW, Glabe CG (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300:486-489.
27. Kozlowski GP, Nilaver G, Zlokovic BV (1990) Immunoneurology: a serum protein afferent limb to the CNS. Circulating regulatory factors and neuroendocrine function (Porter JC, ed), pp 345-370. New York: Plenum.
28. LaRue B, Hogg E, Sagare A, Jovanovic S, Maness L, Maurer C, Deane R, Zlokovic BV (2004) Method for measurement of the blood-brain barrier permeability in the perfused mouse brain: application to amyloid-beta peptide in wild type and Alzheimer's Tg 2576 mice. J Neurosci Methods 138:233-242.
29. Lemere CA, Spooner ET, LaFrancois J, Malester B, Mori C, Leverone JF, Matsuoka Y, Taylor JW, DeMattos RB, Holtzman DM, Clements JD, Selkoe DJ, Duff KE (2003) Evidence for peripheral clearance of cerebral Aβ protein following chronic, active Aβ immunization in PSAPP mice. Neurobiol Dis 14:10-18.
30. LeVine III H (2004) Alzheimer's β-peptide oligomer formation at physiologic concentrations. Anal Biochem 335:81-90.
31. Martel CL, Mackic JB, Matsubara E, Governale S, Miguel C, Miao W, McComb JG, Frangione B, Ghiso J, Zlokovic BV (1997) Isoform-specific effects of apolipoproteins E2, E3, and E4 on cerebral capillary sequestration and blood-brain barrier transport of circulating Alzheimer's amyloid beta. J Neurochem 69:1995-2004.
32. Matsuoka Y, Saito M, LaFrancois J, Saito M, Taylor K, Olm V, Wang L, Casey E, Lu Y, Shiratori C, Lemere C, Duff K (2003) Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to Aβ-amyloid. J Neurosci 23:29-33.
33. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCario G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW (2000) Aβ peptide immunization prevents memory loss in an animal model of Alzheimer's disease. Nature 408:982-985.
34. Nicoll JAR, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat Med 9:448-452.
35. Ober RJ, Martinez C, Lai X, Zhou J, Ward SE (2004) Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level. Proc Natl Acad Sci USA 101:11076-11081.
36. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM (2004) Aβ immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43:321-332.
37. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubios B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C (2003) Subacute meningeoencephalitis in a subset of patients with AD after Aβ 42 immunization. Neurology 61:46-54.
38. Pan W, Solomon B, Maness LM, Kastin AJ (2002) Antibodies to β-amyloid decrease the blood-to-brain transfer of β-amyloid peptide. Exp Biol Med 227:609-615.
39. Pardridge WM (1991) Antibody delivery through the blood-brain barrier. In Peptide drug delivery to the brain (Pardridge WM, ed), pp 219-238. New York: Raven.
40. Paresce DM, Chung H, Maxfield FR (1997) Slow degradation of aggregates of the Alzheimer's disease amyloid β-protein by microglia cells. J Biol Chem 272:29390-29397.
41. Ravetch JV, Bolland S (2001) IgG Fc receptors. Annu Rev Immunol 19:275-290.
42. Roopenian DC, Christianson GJ, Sproule TJ, Brown AC, Akilesh S, Jung N, Petkova S, Avanessian L, Choi EY, Shaffer DJ, Eden PA, Anderson CL (2003) The MHC1-like IgG receptor controls perinatal IgG transport, IgG homeostasis and fate of IgG-Fc-coupled drugs. J Immunol 170:3528-3533.
43. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano M, Shopp G, Vasquez G, Vandevert C, et al. (1999) Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400:173-177.
44. Schlachetzki F, Zhu C, Pardridge WM (2002) Expression of the neonatal Fc receptor (FcRn) at the blood-brain barrier. J Neurochem 81:203-206.
45. 1-40 peptide from brain by low-density lipoprotein receptor-related protein-1 at the blood-brain barrier. J Clin Invest 106:1489-1499.
46. Sigurdsson EM, Scholtzova H, Mehta PD, Frangione B, Wisniewski T (2001) Immunization with a nontoxic/nonfibrillar amyloid-β homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am J Pathol 159:439-447.
47. Tanzi RE, Moir RD, Wagner SL (2004) Clearance of Alzheimer's Aβ peptide; the many roads to perdition. Neuron 43:605-608.
48. 125I to high specific activity. Biochim Biophys Acta 251:363-366.
49. Wilcock DM, DiCarlo G, Henderson D, Jackson J, Clarke K, Ugen KE, Gordon MN, Morgan D (2003) Intracranially administered anti-Aβ antibody reduce β-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci 23:3745-3759.
50. Wu Z, Hofman FM, Zlokovic BV (2003) A simple method for isolation and characterization of mouse brain microvascular endothelial cells. J Neurosci Methods 130:53-63.
51. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen P, Kayed R, Glabe CG, Frautschy SA, Cole GM (2005) Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 280:5892-5901.
52. Yoshida M, Claypool SM, Wagner JS, Mizoguchi E, Mizoguchi A, Roopenian DC, Lencer WI, Blumberg RS (2004) Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells. Immunity 20:769-783.
53. Zlokovic BV (2004) Clearing amyloid through the blood-brain barrier. J Neurochem 89:807-811.
54. Zlokovic BV (2005) Neurovascular mechanisms of Alzheimer's neurode-generation. Trends Neurosci 28:202-208.
55. Zlokovic BV, Skundric DS, Segal MB, Lipovac MN, Mackic JB, Davson H (1990) A saturable mechanism for transport of immunoglobulin G across the blood-brain barrier of the guinea pig. Exp Neurol 107:263-270.
56. Zlokovic BV, Mackic JB, Wang L, McComb JG, McDonough A (1993) Differential expression of Na,K-ATPase alpha and beta subunit isoforms at the blood-brain barrier and the choroid plexus. J Biol Chem 268:8019-8025.